Precigen, Inc. (PGEN)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$4.22-16.60%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · PGEN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 33.9% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name has been missing across recent quarters and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 116 industry peers · Company calendar date is not available
PGEN — earnings in line
Dated 2026-11-05
Results of Operations and Financial Condition. Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated November 4, 2026, reporting its financial results for the quarter ended September 30, 2026. This information, including the Exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly s…
Why it matters: The two Phase 2 trials are ongoing, but the inputs give no new trial results. A clear update can show whether the program is advancing.
Watch forBy December 31, Precigen reports a new PRGN-2009 trial milestone or shares trial results.
Also watch forBy December 31, Precigen reports a trial delay, pause, or stop for either Phase 2 study.
Why it matters: The EMA is reviewing PAPZIMEOS for adults with RRP. Approval would open a path to sales in Europe; a rejection would block that path.
Watch forThe EMA grants marketing approval for PAPZIMEOS for adults with RRP.
Also watch forThe EMA rejects the application or asks Precigen to withdraw it.
Why it matters: Management says PAPZIMEOS sales can fund the company to break-even by the end of 2026. Missing that goal would raise pressure on its cash balance.
Worry ifA company report says cash flow break-even was reached by December 31, 2026.
Less concerning ifA company report says Precigen did not reach cash flow break-even by December 31, 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$252 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $744 loss on $10,000 · 7.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,070 loss on $10,000 · 50.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.